Trials / Recruiting
RecruitingNCT06932757
Adjuvant Quisinostat in High-Risk Uveal Melanoma
Phase 2 Trial of Adjuvant Quisinostat in High-Risk Uveal Melanoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 63 (estimated)
- Sponsor
- University of Miami · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if giving participants quisinostat will prevent participants' uveal melanoma tumor from spreading. The researchers want to find out the effects that quisinostat has on participants' condition.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Quisinostat | Participants will receive 12 mg of Quisinostat via capsule to be taken orally three times per week of each 21 day cycle. |
Timeline
- Start date
- 2025-05-27
- Primary completion
- 2030-05-27
- Completion
- 2030-05-27
- First posted
- 2025-04-17
- Last updated
- 2025-06-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06932757. Inclusion in this directory is not an endorsement.